Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson's disease

Journal of Neurology Neurosurgery and Psychiatry

Volumn 69, Issue 5, 2000, Pages 590-594

  Clarke, C E ^a,b   Davies, P ^a  

^a CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Apomorphine; Levodopa; Parkinson's disease; Systematic review

Indexed keywords

APOMORPHINE; DECARBOXYLASE INHIBITOR; DOMPERIDONE; LEVODOPA;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DRUG RESPONSE; DRUG SENSITIVITY; HEALTH CARE COST; HUMAN; IDIOPATHIC DISEASE; MEDICAL LITERATURE; META ANALYSIS; MOTOR DYSFUNCTION; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

APOMORPHINE; DIAGNOSTIC TESTS, ROUTINE; HUMANS; LEVODOPA; PARKINSON DISEASE; SENSITIVITY AND SPECIFICITY;

EID: 0033793666     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.69.5.590     Document Type: Article

References (22)

1. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinicopathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-1.
2. Eardley I, Quinn NP, Fowler CJ, et al. The value of urethral sphincter electromyography in the differential diagnosis of parkinsonism. Br J Urol 1989;64:360-2.
3. Kimber JR, Watson L, Mathias CJ. Distinction of idiopathic Parkinson's disease from multiple-system atrophy by stimulation of growth-hormone release with clonidine. Lancet 1997;349:1877-81.
4. Clarke CE, Ray PS, Speller JM. Failure of the clonidine growth hormone stimulation test to differentiate multiple system atrophy from advanced idiopathic Parkinson's disease. Lancet 1999;353:1329-30.
5. Tranchant C, Guiraud-Chaumeil C, Warter JM. Stimulation of growth hormone release with clonidine is not a good test to distinguish Parkinson's disease from multiple system atrophy. Mov Disord 1998;13(suppl 2):197.
6. Brooks DJ. PET and SPECT studies in Parkinson's disease. In: Quinn NP, ed. Parkinsonism. London: Bailliere Tindall; 1997:69-87.
7. Schulz JB, Skalej M, Wedekind D, et al. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's disease from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999;45:65-74.
8. Fleiss JL. Statistical methods for rates and proportions. Chichester: John Wiley, 1973.
9. D Costa DF, Sheehan LJ, Phillips PA, et al. The levodopa test in Parkinson's disease. Age Ageing 1995;24:210-2.
10. Hughes AJ, Lees AJ, Stern GM. Challenge tests to predict the dopaminergic response in untreated Parkinson's disease. Neurology 1991;41:1723-5.
11. Gasser T, Schwarz J, Arnold G, et al. Apomorphine test for dopaminergic responsiveness in patients with previously untreated Parkinson's disease. Arch Neurol 1992;49:1131-4.
12. 123I-iodobenzamide-SPECT in 83 patients with de novo parkinsonism. Neurology 1993;43(suppl 6):S17-20.
13. Oertel WH, Gasser T, Ippisch R, et al. Apomorphine test for dopaminergic responsiveness. Lancet 1989;335:1262-3.
14. Hughes AJ, Lees AJ, Stern GM. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet 1990;336:32-4.
15. D Costa DF, Abbott RJ, Pye IF, et al. The apomorphine test in parkinsonian syndromes. J Neurol Neurosurg Psychiatry 1991;54:870-2.
16. 123I IBZM-SPECT. Mov Disord 1993;8:453-8.
17. Bonuccelli U, Piccini P, Del Dotto P, et al. Apomorphine test for dopaminergic responsiveness: a dose assessment study. Mov Disord 1993;8:158-64.
18. Linazasoro G. The apomorphine test in Parkinson's disease: diagnostic value. Neurologia 1993;8:288-90.
19. Roth J, Ruzicka E, Mecir P. The apomorphine test in the differential diagnosis of Parkinsonism. Initial experience. Cas Lek Cesk 1994;133:665-7.
20. Miranda M, Saez D. Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease. Rev Med Chil 1995;123:326-9.
21. Zappia M, Montesanti R, Colao R, et al. Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. Mov Disord 1997;12:103-6.
22. Rascol O, Brooks D, Korczyn A, et al. A five year study of the incidence of dyskinesia in patients with early Parkinson's desease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-91.